APA aipamena

Burger, J. A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Tedeschi, A., . . . Kipps, T. J. (2019). Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia.

Chicago Style aipamena

Burger, Jan A., et al. "Long-term Efficacy and Safety of First-line Ibrutinib Treatment for Patients With CLL/SLL: 5 Years of Follow-up From the Phase 3 RESONATE-2 Study." Leukemia 2019.

MLA aipamena

Burger, Jan A., et al. "Long-term Efficacy and Safety of First-line Ibrutinib Treatment for Patients With CLL/SLL: 5 Years of Follow-up From the Phase 3 RESONATE-2 Study." Leukemia 2019.